<article xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article"><front><journal-meta><journal-id journal-id-type="nlm-ta">BMC Neurol</journal-id><journal-title>BMC Neurology</journal-title><issn pub-type="epub">1471-2377</issn><publisher><publisher-name>BioMed Central</publisher-name><publisher-loc>London</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">16719908</article-id><article-id pub-id-type="pmc">1501038</article-id><article-id pub-id-type="publisher-id">1471-2377-6-19</article-id><article-id pub-id-type="doi">10.1186/1471-2377-6-19</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title>Monthly intravenous methylprednisolone in relapsing-remitting multiple sclerosis - reduction of enhancing lesions, T2 lesion volume and plasma prolactin concentrations</article-title></title-group><contrib-group><contrib id="A1" equal-contrib="yes" corresp="yes" contrib-type="author"><name><surname>Then Bergh</surname><given-names>Florian </given-names></name><xref ref-type="aff" rid="I1">1</xref><xref ref-type="aff" rid="I8">8</xref><email>ThenBerF@medizin.uni-leipzig.de</email></contrib><contrib id="A2" equal-contrib="yes" contrib-type="author"><name><surname>Kümpfel</surname><given-names>Tania</given-names></name><xref ref-type="aff" rid="I1">1</xref><xref ref-type="aff" rid="I9">9</xref><email>Tania.Kuempfel@med.uni-muenchen.de</email></contrib><contrib id="A3" contrib-type="author"><name><surname>Schumann</surname><given-names>Erina</given-names></name><xref ref-type="aff" rid="I2">2</xref><email>schumann@radiologie-friedberg.de</email></contrib><contrib id="A4" contrib-type="author"><name><surname>Held</surname><given-names>Ulrike</given-names></name><xref ref-type="aff" rid="I3">3</xref><email>held@slcmsr.org</email></contrib><contrib id="A5" contrib-type="author"><name><surname>Schwan</surname><given-names>Michaela</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>michaela.schwan@arcor.de</email></contrib><contrib id="A6" contrib-type="author"><name><surname>Blazevic</surname><given-names>Mirjana</given-names></name><xref ref-type="aff" rid="I4">4</xref><email>mai8@gmx.de</email></contrib><contrib id="A7" contrib-type="author"><name><surname>Wismüller</surname><given-names>Axel</given-names></name><xref ref-type="aff" rid="I4">4</xref><email>Axel@Wismueller.de</email></contrib><contrib id="A8" contrib-type="author"><name><surname>Holsboer</surname><given-names>Florian</given-names></name><xref ref-type="aff" rid="I5">5</xref><email>holsboer@mpipsykl.mpg.de</email></contrib><contrib id="A9" contrib-type="author"><name><surname>Yassouridis</surname><given-names>Alexander</given-names></name><xref ref-type="aff" rid="I6">6</xref><email>yassou@mpipsykl.mpg.de</email></contrib><contrib id="A10" contrib-type="author"><name><surname>Uhr</surname><given-names>Manfred</given-names></name><xref ref-type="aff" rid="I7">7</xref><email>uhr@mpipsykl.mpg.de</email></contrib><contrib id="A11" contrib-type="author"><name><surname>Weber</surname><given-names>Frank</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>fweber@mpipsykl.mpg.de</email></contrib><contrib id="A12" contrib-type="author"><name><surname>Daumer</surname><given-names>Martin</given-names></name><xref ref-type="aff" rid="I3">3</xref><email>daumer@slcmsr.org</email></contrib><contrib id="A13" contrib-type="author"><name><surname>Trenkwalder</surname><given-names>Claudia</given-names></name><xref ref-type="aff" rid="I1">1</xref><xref ref-type="aff" rid="I10">10</xref><email>ctrenkwalder@gmx.de</email></contrib><contrib id="A14" contrib-type="author"><name><surname>Auer</surname><given-names>Dorothee P</given-names></name><xref ref-type="aff" rid="I2">2</xref><xref ref-type="aff" rid="I11">11</xref><email>Dorothee.Auer@nottingham.ac.uk</email></contrib></contrib-group><aff id="I1"><label>1</label>Section of Neurology, Max-Planck-Institut für Psychiatrie, München, Germany</aff><aff id="I2"><label>2</label>Section of Neuroradiology, Max-Planck-Institut für Psychiatrie, München, Germany</aff><aff id="I3"><label>3</label>Sylvia Lawry Center for Multiple Sclerosis Research, München, Germany</aff><aff id="I4"><label>4</label>Department of Diagnostic Radiology, Ludwig-Maximilians-Universität, München, Germany</aff><aff id="I5"><label>5</label>Section of Neuroendocrinology, Max-Planck-Institut für Psychiatrie, München, Germany</aff><aff id="I6"><label>6</label>Section of Satistics, Max-Planck-Institut für Psychiatrie, München, Germany</aff><aff id="I7"><label>7</label>Section of Clinical Chemistry, Max-Planck-Institut für Psychiatrie, München, Germany</aff><aff id="I8"><label>8</label>Klinik und Poliklinik für Neurologie, Universität Leipzig, Leipzig, Germany</aff><aff id="I9"><label>9</label>Institute of Clinical Neuroimmunology, Klinikum Großhadern, Ludwig-Maximilians-Universität, München, Germany</aff><aff id="I10"><label>10</label>Paracelsus-Klinik, Kassel, Germany</aff><aff id="I11"><label>11</label>Department of Neuroradiology, University of Nottingham, UK</aff><pub-date pub-type="collection"><year>2006</year></pub-date><pub-date pub-type="epub"><day>23</day><month>5</month><year>2006</year></pub-date><volume>6</volume><fpage>19</fpage><lpage>19</lpage><ext-link ext-link-type="uri" xlink:href="http://www.biomedcentral.com/1471-2377/6/19"></ext-link><history><date date-type="received"><day>30</day><month>1</month><year>2006</year></date><date date-type="accepted"><day>23</day><month>5</month><year>2006</year></date></history><permissions><copyright-statement>Copyright © 2006 Then Bergh et al; licensee BioMed Central Ltd.</copyright-statement><copyright-year>2006</copyright-year><copyright-holder>Then Bergh et al; licensee BioMed Central Ltd.</copyright-holder><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/2.0"><p>This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/2.0"></ext-link>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</p></license></permissions><abstract><sec><title><offsets xml_i="6378" xml_f="6388" txt_i="11" txt_f="21">Background</offsets></title><p><offsets xml_i="6399" xml_f="6737" txt_i="22" txt_f="360">Intravenous methylprednisolone (IV-MP) is an established treatment for multiple sclerosis (MS) relapses, accompanied by rapid, though transient reduction of gadolinium enhancing (Gd+) lesions on brain MRI. Intermittent IV-MP, alone or with immunomodulators, has been suggested but insufficiently studied as a strategy to prevent relapses.</offsets></p></sec><sec sec-type="methods"><title><offsets xml_i="6778" xml_f="6785" txt_i="362" txt_f="369">Methods</offsets></title><p><offsets xml_i="6796" xml_f="7545" txt_i="370" txt_f="1119">In an open, single-cross-over study, nine patients with relapsing-remitting MS (RR-MS) underwent cranial Gd-MRI once monthly for twelve months. From month six on, they received a single i.v.-infusion of 500 mg methylprednisolone (and oral tapering for three days) after the MRI. Primary outcome measure was the mean number of Gd+ lesions during treatment vs. baseline periods; T2 lesion volume and monthly plasma concentrations of cortisol, ACTH and prolactin were secondary outcome measures. Safety was assessed clinically, by routine laboratory and bone mineral density measurements. Soluble immune parameters (sTNF-RI, sTNF-RII, IL1-ra and sVCAM-1) and neuroendocrine tests (ACTH test, combined dexamethasone/CRH test) were additionally analyzed.</offsets></p></sec><sec><title><offsets xml_i="7567" xml_f="7574" txt_i="1121" txt_f="1128">Results</offsets></title><p><offsets xml_i="7585" xml_f="8331" txt_i="1129" txt_f="1875">Comparing treatment to baseline periods, the number of Gd+ lesions/scan was reduced in eight of the nine patients, by a median of 43.8% (p = 0.013, Wilcoxon). In comparison, a pooled dataset of 83 untreated RR-MS patients from several studies, selected by the same clinical and MRI criteria, showed a non-significant decrease by a median of 14% (p = 0.32). T2 lesion volume decreased by 21% during treatment (p = 0.001). Monthly plasma prolactin showed a parallel decline (p = 0.027), with significant cross-correlation with the number of Gd+ lesions. Other hormones and immune system variables were unchanged, as were ACTH test and dexamethasone-CRH test. Treatment was well tolerated; routine laboratory and bone mineral density were unchanged.</offsets></p></sec><sec><title><offsets xml_i="8353" xml_f="8363" txt_i="1877" txt_f="1887">Conclusion</offsets></title><p><offsets xml_i="8374" xml_f="8448" txt_i="1888" txt_f="1962">Monthly IV-MP reduces inflammatory activity and T2 lesion volume in RR-MS.</offsets></p></sec></abstract></article-meta></front><body><sec><title><offsets xml_i="8510" xml_f="8520" txt_i="1971" txt_f="1981">Background</offsets></title><p><offsets xml_i="8531" xml_f="8686" txt_i="1982" txt_f="2137">Intravenous methylprednisolone (IV-MP), 500–1000 mg for 3–5 days, is an established treatment for acute relapses of multiple sclerosis, speeding recovery [</offsets><xref ref-type="bibr" rid="B1"><offsets xml_i="8717" xml_f="8718" txt_i="2137" txt_f="2138">1</offsets></xref><offsets xml_i="8725" xml_f="8726" txt_i="2138" txt_f="2139">,</offsets><xref ref-type="bibr" rid="B2"><offsets xml_i="8757" xml_f="8758" txt_i="2139" txt_f="2140">2</offsets></xref><offsets xml_i="8765" xml_f="9029" txt_i="2140" txt_f="2404">]. It does not prevent future relapses. However, a study in isolated optic neuritis suggested that a single course of IV-MP may delay the occurrence of another episode of inflammatory demyelination and thus conversion to definite MS according to Poser's criteria [</offsets><xref ref-type="bibr" rid="B3"><offsets xml_i="9060" xml_f="9061" txt_i="2404" txt_f="2405">3</offsets></xref><offsets xml_i="9068" xml_f="9069" txt_i="2405" txt_f="2406">,</offsets><xref ref-type="bibr" rid="B4"><offsets xml_i="9100" xml_f="9101" txt_i="2406" txt_f="2407">4</offsets></xref><offsets xml_i="9108" xml_f="9277" txt_i="2407" txt_f="2576">]. Repeated administration of IV-MP in regular intervals may extend these beneficial effects, but this approach has not been fully evaluated and requires further study [</offsets><xref ref-type="bibr" rid="B5"><offsets xml_i="9308" xml_f="9309" txt_i="2576" txt_f="2577">5</offsets></xref><offsets xml_i="9316" xml_f="9442" txt_i="2577" txt_f="2703">]. In secondary progressive MS, IV-MP every two months showed partial, dose-dependant benefit in several secondary endpoints [</offsets><xref ref-type="bibr" rid="B6"><offsets xml_i="9473" xml_f="9474" txt_i="2703" txt_f="2704">6</offsets></xref><offsets xml_i="9481" xml_f="9660" txt_i="2704" txt_f="2883">]. In relapsing-remitting MS, a five-day course of IV-MP every four to six months slowed progression of MRI measures of brain atrophy, as compared to treatment for relapses only [</offsets><xref ref-type="bibr" rid="B7"><offsets xml_i="9691" xml_f="9692" txt_i="2883" txt_f="2884">7</offsets></xref><offsets xml_i="9699" xml_f="9701" txt_i="2884" txt_f="2886">].</offsets></p><p><offsets xml_i="9708" xml_f="9970" txt_i="2887" txt_f="3149">The mechanisms underlying the beneficial effects of corticosteroids in MS remain incompletely understood. Rapid reduction of inflammatory blood-brain-barrier (BBB) disruption, as shown by disappearance of gadolinium (Gd) enhancement after few days of treatment [</offsets><xref ref-type="bibr" rid="B8"><offsets xml_i="10001" xml_f="10002" txt_i="3149" txt_f="3150">8</offsets></xref><offsets xml_i="10009" xml_f="10010" txt_i="3150" txt_f="3151">-</offsets><xref ref-type="bibr" rid="B10"><offsets xml_i="10042" xml_f="10044" txt_i="3151" txt_f="3153">10</offsets></xref><offsets xml_i="10051" xml_f="10287" txt_i="3153" txt_f="3389">], is a prominent effect. Corticosteroids are also potent immunomodulatory drugs, inhibiting the expression of inflammatory mediators (including TNF and leukocyte-endothelial cell adhesion molecules) and cellular immunity (reviewed in [</offsets><xref ref-type="bibr" rid="B11"><offsets xml_i="10319" xml_f="10321" txt_i="3389" txt_f="3391">11</offsets></xref><offsets xml_i="10328" xml_f="10405" txt_i="3391" txt_f="3468">]). Further, the endocrine and immune systems closely interact (reviewed in [</offsets><xref ref-type="bibr" rid="B12"><offsets xml_i="10437" xml_f="10439" txt_i="3468" txt_f="3470">12</offsets></xref><offsets xml_i="10446" xml_f="10584" txt_i="3470" txt_f="3608">]), with ACTH, cortisol, prolactin (PRL) and growth hormone (hGH) being most often implicated in the regulation of the immune system. We [</offsets><xref ref-type="bibr" rid="B13"><offsets xml_i="10616" xml_f="10618" txt_i="3608" txt_f="3610">13</offsets></xref><offsets xml_i="10625" xml_f="10626" txt_i="3610" txt_f="3611">,</offsets><xref ref-type="bibr" rid="B14"><offsets xml_i="10658" xml_f="10660" txt_i="3611" txt_f="3613">14</offsets></xref><offsets xml_i="10667" xml_f="10681" txt_i="3613" txt_f="3627">] and others [</offsets><xref ref-type="bibr" rid="B15"><offsets xml_i="10713" xml_f="10715" txt_i="3627" txt_f="3629">15</offsets></xref><offsets xml_i="10722" xml_f="10869" txt_i="3629" txt_f="3776">] have described a disturbed regulation of the hypothalamo-pituitary-adrenal (HPA) axis in MS, as well as hyperprolactinemia during acute attacks [</offsets><xref ref-type="bibr" rid="B16"><offsets xml_i="10901" xml_f="10903" txt_i="3776" txt_f="3778">16</offsets></xref><offsets xml_i="10910" xml_f="11098" txt_i="3778" txt_f="3966">]. While causal relations are at present difficult to establish, corticosteroids do affect the secretion of several other hormones, and may thus have indirect effects on the immune system.</offsets></p><p><offsets xml_i="11105" xml_f="11414" txt_i="3967" txt_f="4276">It is unknown if these effects remain active with regular administration. In order to study the effect of pulsed corticosteroids on several of these aspects, we administered a single infusion of MP, once per month, to RR-MS patients. Based on guidelines derived from natural history and treatment trial data [</offsets><xref ref-type="bibr" rid="B17"><offsets xml_i="11446" xml_f="11448" txt_i="4276" txt_f="4278">17</offsets></xref><offsets xml_i="11455" xml_f="11456" txt_i="4278" txt_f="4279">,</offsets><xref ref-type="bibr" rid="B18"><offsets xml_i="11488" xml_f="11490" txt_i="4279" txt_f="4281">18</offsets></xref><offsets xml_i="11497" xml_f="11626" txt_i="4281" txt_f="4410">], we designed a single-cross-over study with a six-month baseline and a six-month treatment period, and determined the impact on</offsets></p><p><offsets xml_i="11633" xml_f="11742" txt_i="4411" txt_f="4520">1. inflammatory disease activity as shown by BBB disruption (frequency of Gd-enhancing lesions on brain MRI),</offsets></p><p><offsets xml_i="11749" xml_f="11773" txt_i="4521" txt_f="4545">2. total T2 lesion load,</offsets></p><p><offsets xml_i="11780" xml_f="11867" txt_i="4546" txt_f="4633">3. plasma hormone concentrations and dynamic measures of neuroendocrine regulation, and</offsets></p><p><offsets xml_i="11874" xml_f="11920" txt_i="4634" txt_f="4680">4. selected plasma markers of immune function.</offsets></p></sec><sec sec-type="methods"><title><offsets xml_i="11961" xml_f="11968" txt_i="4682" txt_f="4689">Methods</offsets></title><sec><title><offsets xml_i="11988" xml_f="12000" txt_i="4690" txt_f="4702">Study design</offsets></title><p><offsets xml_i="12011" xml_f="12119" txt_i="4703" txt_f="4811">Participation in this open-label, single-cross-over study was offered to patients with clinically definite [</offsets><xref ref-type="bibr" rid="B19"><offsets xml_i="12151" xml_f="12153" txt_i="4811" txt_f="4813">19</offsets></xref><offsets xml_i="12160" xml_f="13220" txt_i="4813" txt_f="5873">], relapsing-remitting MS, followed in a natural history study with monthly Gd-enhanced MRI. Patients could enter that study no earlier than three months after the last relapse or course of IV-MP. In each individual patient, scans were performed at the same time of the day, and blood was drawn from an antecubital vein before each scan. We first selected those patients who had at least one Gd-enhancing lesion on the first three scans, and continued monthly visits for another three months. Final inclusion in the treatment trial required that the first six monthly scans showed at least three Gd-enhancing lesions (i.e. a mean of 0.5 Gd+ lesions per scan). Further inclusion criteria were: one or more relapses during the two years before the first MRI scan, contraindication to immunosuppressive or immunomodulatory therapy or decline of these therapies by the patient, and no contraindications to glucocorticoid treatment. Upon inclusion, monthly MRI and blood sampling was continued until month 12. Treatment started after the MRI at month 6 (see below).</offsets></p><p><offsets xml_i="13227" xml_f="13476" txt_i="5874" txt_f="6123">The study was performed and funded by the participating institutions, with no external funding. It was approved by the ethics committee of the Bavarian State Board of Physicians (Bayerische Landesärztekammer). Patients gave written informed consent.</offsets></p></sec><sec><title><offsets xml_i="13498" xml_f="13506" txt_i="6125" txt_f="6133">Patients</offsets></title><p><offsets xml_i="13517" xml_f="13746" txt_i="6134" txt_f="6363">Twenty-five patients were screened by three monthly MRI scans. Ten patients fulfilled the inclusion criteria, but we excluded one patient with a very high baseline activity to reduce the risk of regression to the mean. See table </offsets><xref ref-type="table" rid="T1"><offsets xml_i="13778" xml_f="13779" txt_i="6363" txt_f="6364">1</offsets></xref><offsets xml_i="13786" xml_f="13882" txt_i="6364" txt_f="6460"> for clinical and demographic characteristics of the finally included nine patients, and figure </offsets><xref ref-type="fig" rid="F1"><offsets xml_i="13912" xml_f="13913" txt_i="6460" txt_f="6461">1</offsets></xref><offsets xml_i="13920" xml_f="14167" txt_i="6461" txt_f="6708"> for a study flow chart. None of the patients had ever been treated with immunosuppressive or immunomodulatory drugs; mean annualized relapse rate during the entire disease duration was 0.68, and during the two years prior to study inclusion, 0.8.</offsets></p></sec><sec><title><offsets xml_i="14189" xml_f="14215" txt_i="6710" txt_f="6736">Magnetic resonance imaging</offsets></title><p><offsets xml_i="14226" xml_f="14864" txt_i="6737" txt_f="7375">Once every month, brain MRI was performed on the same 1.5T Signa Echospeed (GE Medical Systems), including axial T1-weighted sequences (TR = 640 ms, TE = 14 ms, 4 mm thick, 1 mm gap) as well as a proton density and T2 weighted dual fast spin echo sequence (TR = 3600 ms, TE = 13 and 91 ms, resp.) and a FLAIR sequence (TR = 10 s, TE = 133 ms, TI = 2200 ms) inherently coregistered with the T1 axial scans. Axial and coronal (3 mm thick, 1.5 mm gap) T1-weighted sequences were acquired after i.v. injection of 0.1 mmol/kg gadolinium chelate (Omniscan(R)), with the interval between injection and first axial scan standardized at 6 minutes.</offsets></p><p><offsets xml_i="14871" xml_f="15258" txt_i="7376" txt_f="7763">The number of Gd-enhancing lesions on brain MRI was determined by a blinded radiologist (E.S.) on the scans presented in random order, with the date of acquisition masked. For each patient, the mean number of active lesions per scan was calculated for baseline and treatment period. To determine lesion volume and BFV, a neural network based image analysis system was used as described [</offsets><xref ref-type="bibr" rid="B20"><offsets xml_i="15290" xml_f="15292" txt_i="7763" txt_f="7765">20</offsets></xref><offsets xml_i="15299" xml_f="16369" txt_i="7765" txt_f="8835">]. Briefly, data preprocessing included manual delineation of the intracranial cavity contents, automatic grey value correction (coil inhomogeneity and interslice differences) and extraction of a small training data subset by interactive contour tracing of regions representing the structure classes: normal appearing grey matter (GM), normal appearing white matter (WM), cerebro-spinal fluid (CSF), and MS lesion. A hierarchical vector quantization approach was then deployed to segment the multi-dimensional image data into five classes: GM, WM, CSF, lesions and other (comprising meninges, vessels). The BFV was determined as the ratio of pixels belonging to either brain, i.e. GM, WM or MS lesions, to those belonging to brain or CSF. CSF segmentation was based on the image information obtained by all acquired MRI sequences; MS-lesions were identified based on T2, PD, and FLAIR data. The segmentation performance compared favorably (higher retest stability) with the more standard region growing segmentation algorithm for T2 lesion load (T2-LL) and angle image [</offsets><xref ref-type="bibr" rid="B21"><offsets xml_i="16401" xml_f="16403" txt_i="8835" txt_f="8837">21</offsets></xref><offsets xml_i="16410" xml_f="16421" txt_i="8837" txt_f="8848">] for BFV [</offsets><xref ref-type="bibr" rid="B20"><offsets xml_i="16453" xml_f="16455" txt_i="8848" txt_f="8850">20</offsets></xref><offsets xml_i="16462" xml_f="16634" txt_i="8850" txt_f="9022">]. T2-LL and BFV were calculated for four time points (start and end of baseline: months 1 and 6; and four weeks after the first and the last MP infusion: months 7 and 12).</offsets></p></sec><sec><title><offsets xml_i="16656" xml_f="16665" txt_i="9024" txt_f="9033">Treatment</offsets></title><p><offsets xml_i="16676" xml_f="16891" txt_i="9034" txt_f="9249">From month six to eleven, patients received 500 mg MP i.v. after each MRI scan, followed by an oral tapering dose of 40, 20 and 10 mg MP for one day each to prevent any potential temporary glucocorticoid deficiency.</offsets></p></sec><sec><title><offsets xml_i="16913" xml_f="16954" txt_i="9251" txt_f="9292">Serum cytokine and hormone concentrations</offsets></title><p><offsets xml_i="16965" xml_f="17632" txt_i="9293" txt_f="9956">Blood was collected, between 15:00 and 18:00 in the afternoon and always before the MRI scan, into tubes containing EDTA and trasylol, and plasma was stored at -80 degC until processing. sTNF-RI, sTNF-RII, IL-1ra and sVCAM1 were quantified by commercial enzyme-linked immunosorbent assay (ELISA) kits (s-TNF-RI and RII: Biosource Europe, Belgium; IL-1ra and VCAM-1: R&amp;D Systems, Minneapolis, USA). Hormone concentrations were measured using commercial radioimmuno (RIA) or chemiluminescence assays (cortisol: RIA, DRG Instruments, Germany; ACTH: RIA, and prolactin: Chemiluminescence Immunoassay, both Nichols Institute Diagnostics, San Juan Capistrano, CA, USA).</offsets></p></sec><sec><title><offsets xml_i="17654" xml_f="17676" txt_i="9958" txt_f="9980">Dexamethasone-CRH test</offsets></title><p><offsets xml_i="17687" xml_f="17783" txt_i="9981" txt_f="10077">The dexamethasone-CRH test (Dex-CRH test) was performed, and values were derived, as described [</offsets><xref ref-type="bibr" rid="B13"><offsets xml_i="17815" xml_f="17817" txt_i="10077" txt_f="10079">13</offsets></xref><offsets xml_i="17824" xml_f="17897" txt_i="10079" txt_f="10152">], once before the start of treatment, and once between months 11 and 12.</offsets></p></sec><sec><title><offsets xml_i="17919" xml_f="17925" txt_i="10154" txt_f="10160">Safety</offsets></title><p><offsets xml_i="17936" xml_f="18012" txt_i="10161" txt_f="10237">In addition to a full physical and neurological examination including EDSS [</offsets><xref ref-type="bibr" rid="B22"><offsets xml_i="18044" xml_f="18046" txt_i="10237" txt_f="10239">22</offsets></xref><offsets xml_i="18053" xml_f="18588" txt_i="10239" txt_f="10774">], blood chemistry (including calcium, phosphate and vitamine D3), blood count, thyroid function tests, urinanalysis and pyrrolidine cross-links in urine were determined monthly. At baseline and after six months of treatment, patients underwent the short ACTH test (i.v. injection of 200 microgram tetracosactid [Synacthen(R), Novartis] at 08:00, with determination of plasma cortisol concentration before and 60 minutes after injection) and CT densitometry of the lumbar spine. All procedures were performed on an outpatient schedule.</offsets></p></sec><sec><title><offsets xml_i="18610" xml_f="18626" txt_i="10776" txt_f="10792">Outcome measures</offsets></title><p><offsets xml_i="18637" xml_f="18809" txt_i="10793" txt_f="10965">The mean number of Gd enhancing lesions per monthly MRI scan was defined as the primary outcome measure. In accordance with published guidelines and sample size estimates [</offsets><xref ref-type="bibr" rid="B17"><offsets xml_i="18841" xml_f="18843" txt_i="10965" txt_f="10967">17</offsets></xref><offsets xml_i="18850" xml_f="18851" txt_i="10967" txt_f="10968">,</offsets><xref ref-type="bibr" rid="B18"><offsets xml_i="18883" xml_f="18885" txt_i="10968" txt_f="10970">18</offsets></xref><offsets xml_i="18892" xml_f="19489" txt_i="10970" txt_f="11567">], we planned to enroll ten patients. Secondary outcome variables were T2 lesion volume and monthly plasma hormone concentrations. Serum immune variables and results of neuroendocrine tests were analysed in an exploratory fashion. Number of relapses, EDSS, routine laboratory results and bone mineral density measures were safety variables, with study termination criteria predefined for the laboratory results. Brain fractional volume (BFV) was determined to control for global changes in brain volume, potentially resulting in false results of T2 volume analyses; BFV was not an outcome measure.</offsets></p></sec><sec><title><offsets xml_i="19511" xml_f="19524" txt_i="11569" txt_f="11582">Data analysis</offsets></title><p><offsets xml_i="19535" xml_f="20519" txt_i="11583" txt_f="12567">According to the data structure, the effect of treatment on the number of active lesions, on hormone and cytokine receptor concentrations was analyzed using the non-parametric Wilcoxon matched-pairs signed-ranks test and a one-factorial univariate analyses of variance (ANOVA) with repeated measures design. The continuous dependent variables were transformed with the ln-transformation [Y = ln (x+1)] before ANOVAs. Associations over time between the number of active lesions to plasma hormone concentrations and immunological parameters were analysed by cross-correlation analysis. Changes of T2-LL and BFV, and all other laboratory results were analyzed by MANOVA, and followed by univariate F-tests where appropriate. As nominal level of significance, p = 0.05 was accepted; it was corrected (according to Bonferroni correction procedure) for all post-hoc tests, in order to keep the type I error less or equal to 0.05. Data are given as mean +/- standard error of the mean (SEM).</offsets></p></sec><sec><title><offsets xml_i="20541" xml_f="20557" txt_i="12569" txt_f="12585">Comparison group</offsets></title><p><offsets xml_i="20568" xml_f="22117" txt_i="12586" txt_f="14135">The comparison group was extracted from the database maintained at the Sylvia Lawry Center for Multiple Sclerosis Research. This database includes clinical and imaging information on patients examined according to clinical trial protocols at separate centers, including untreated control groups from several large clinical trials and natural history studies. Patients were selected based on the following criteria: A diagnosis of relapsing-remitting multiple sclerosis, no current immunosuppressive or immunomodulatory treatment, longitudinal Gd-MRI follow-up over twelve months, presence of at least 1 new Gd+ lesion during the first three months, and at least three new Gd+ lesions during the first six months. This yielded a group of 83 patients (55 females, mean age 34.4 +/- 0.8 years, mean duration of disease of 7.5 +/- 0.6 years). The MRI protocols applied 0.1 mmol/kg of gadolinium chelate. The mean interval between injection and post-contrast T1w imaging was 5.7 minutes; the delay was 5 minutes in 69 of the selected 83 patients, one minute in one patient, and between 7.5 and 15 minutes in the remaining patients. Monthly scans over the entire twelve-month period were available for seven patients; among the remaining patients, four to six scans over the first six-month-period were available for 75 patients, and for both six-month-periods for 57 patients. The mean number of new Gd+ lesions was calculated for each individual patient for the first and the second six-month-period and expressed as mean number of Gd+ lesions per scan.</offsets></p></sec></sec><sec><title><offsets xml_i="22145" xml_f="22152" txt_i="14138" txt_f="14145">Results</offsets></title><p><offsets xml_i="22163" xml_f="22375" txt_i="14146" txt_f="14358">During the treatment period, the mean number of active lesions per scan was reduced in eight of the nine patients, by 14 to 100% compared to the baseline period; the number increased by 21% in one patient (table </offsets><xref ref-type="table" rid="T1"><offsets xml_i="22407" xml_f="22408" txt_i="14358" txt_f="14359">1</offsets></xref><offsets xml_i="22415" xml_f="22999" txt_i="14359" txt_f="14943">). The median rate of reduction was 43.8%, and the mean rate of reduction was 46.4%. The mean number of active lesions averaged over the group was reduced from 3.55 per month (baseline period) to 2.15 (treatment period, a reduction by 39.4%), statistically significant by Wilcoxon matched-pairs signed-ranks test (two-tailed p = 0.013). Analysis of variance also revealed a significant effect of time [Wilk's aver. multivariate test of significance; effect of time: F(11,88) = 2.15, p = 0.025]. The anti-inflammatory effect was apparent from the first scan on treatment (T1 in figure </offsets><xref ref-type="fig" rid="F2"><offsets xml_i="23029" xml_f="23030" txt_i="14943" txt_f="14944">2</offsets></xref><offsets xml_i="23037" xml_f="23271" txt_i="14944" txt_f="15178">). Tests with polynomial contrasts in ANOVA revealed that the mean number of enhancing lesions can be optimally fitted by a polynomial curve of third order (effect of polynomial contrast of 3rd order: F(1,8) = 6.35, sig of F = 0.036).</offsets></p><p><offsets xml_i="23278" xml_f="23811" txt_i="15179" txt_f="15712">The comparison group had a mean of 2.95 Gd+ lesions per scan during the first six months of observation. Over the next six months, the frequency of new Gd+ lesions per scan increased or decreased over a wide range in indidvidual patients, yielding a median rate of change of -14.3% (reduction), but a mean rate of change of +15.2% (increase). When analyzing the group averages, the mean number of new Gd+ lesions was reduced to 2.76 Gd+ lesions per scan (a reduction by 6.4%). These changes were not significant (Wilcoxon, p = 0.32).</offsets></p><p><offsets xml_i="23818" xml_f="23965" txt_i="15713" txt_f="15860">In the study population, there was also a significant time effect on T2 lesion load (Wilk's multivariate test for effect of time, p = 0.002; table </offsets><xref ref-type="table" rid="T2"><offsets xml_i="23997" xml_f="23998" txt_i="15860" txt_f="15861">2</offsets></xref><offsets xml_i="24005" xml_f="24456" txt_i="15861" txt_f="16309">). Over the five-month baseline period, T2-LL increased by 13% (p &lt; 0.001). The first MP infusion led to a decrease in T2-LL (by 8%, p = 0.021 for comparison of month 7 to month 6, the last baseline scan), and repeated MP infusions further decreased T2-LL until month 12 (p = 0.001 for comparison to month 7 or to month 6), representing a total decrease of 21% during the treatment period. The changes in BFV were not significant (p = 0.086; table </offsets><xref ref-type="table" rid="T2"><offsets xml_i="24488" xml_f="24489" txt_i="16309" txt_f="16310">2</offsets></xref><offsets xml_i="24496" xml_f="24498" txt_i="16310" txt_f="16312">).</offsets></p><p><offsets xml_i="24505" xml_f="24691" txt_i="16313" txt_f="16499">IV-MP treatment exhibited a significant effect on mean plasma prolactin concentrations during baseline vs. treatment period, with lower concentrations during the treatment period (Table </offsets><xref ref-type="table" rid="T3"><offsets xml_i="24723" xml_f="24724" txt_i="16499" txt_f="16500">3</offsets></xref><offsets xml_i="24731" xml_f="25249" txt_i="16500" txt_f="17015">; Wilks multivariate test in MANOVA (F(1,8) = 7.32, p = 0.027). Cross correlation coefficients revealed significant associations of lag -1 between plasma prolactin concentrations and the number of active lesions on MRI (Cross correlation coefficient: r = 0.728, p &lt; 0.05). This means that prolactin levels increase or decrease one month before a corresponding change in the number of active lesions is observed on MRI. Cortisol and ACTH did not differ significantly between the baseline and treatment period (table </offsets><xref ref-type="table" rid="T3"><offsets xml_i="25281" xml_f="25282" txt_i="17015" txt_f="17016">3</offsets></xref><offsets xml_i="25289" xml_f="25358" txt_i="17016" txt_f="17085">). Also, results of the dexamethasone-CRH test were unchanged (table </offsets><xref ref-type="table" rid="T3"><offsets xml_i="25390" xml_f="25391" txt_i="17085" txt_f="17086">3</offsets></xref><offsets xml_i="25398" xml_f="25540" txt_i="17086" txt_f="17228">). There was no significant effect of treatment on soluble TNF receptors, IL-1 receptor antagonist or sVCAM1 (which increased slightly; table </offsets><xref ref-type="table" rid="T4"><offsets xml_i="25572" xml_f="25573" txt_i="17228" txt_f="17229">4</offsets></xref><offsets xml_i="25580" xml_f="25582" txt_i="17229" txt_f="17231">).</offsets></p><p><offsets xml_i="25589" xml_f="26429" txt_i="17232" txt_f="18072">Four relapses occurred during the baseline period (three treated by three-day courses of IV-MP, and MRI performed no earlier than ten days afterwards), and two mild relapses during the treatment period (no additional steroids administered). The relapses occurred in individual patients, and all recovered to the previous level of impairment. The mean EDSS score was almost unchanged between baseline (1.45 +/- 0.30) and end of study (1.40 +/- 0.37). Apart from occasional sleep disturbance on the day of infusion and mild flush-like sensations immediately following the infusion, treatment was well tolerated. Results of routine laboratory investigations were unchanged (not shown). All patients had an adequate rise of plasma cortisol after i.v. tetracosactid ("short ACTH test"), both at baseline and after six months of treatment (table </offsets><xref ref-type="table" rid="T3"><offsets xml_i="26461" xml_f="26462" txt_i="18072" txt_f="18073">3</offsets></xref><offsets xml_i="26469" xml_f="26768" txt_i="18073" txt_f="18372">). Biochemical measures of bone metabolism (calcium, phosphate, vitamin D3 in serum, and pyrrolidine cross-links in urine, data not shown) as well as bone mineral density (CT densitometry of the lumbar spine: 140.34 +/- 15.79 before, 135.50 +/- 15.93 after treatment) were not significantly changed.</offsets></p></sec><sec><title><offsets xml_i="26790" xml_f="26800" txt_i="18374" txt_f="18384">Discussion</offsets></title><p><offsets xml_i="26811" xml_f="27305" txt_i="18385" txt_f="18879">We show here that a single monthly infusion of 500 mg methylprednisolone with a three-day oral taper can reduce inflammatory disease activity in patients with relapsing-remitting MS, without clinically relevant side effects. Our data support and extend two previous studies of pulsed steroid treatment in MS. In RR-MS patients, regular courses of IV-MP every four to six months, as compared to treatment for clinical relapses only, delayed accumulation of T1 hypointensities and brain atrophy [</offsets><xref ref-type="bibr" rid="B7"><offsets xml_i="27336" xml_f="27337" txt_i="18879" txt_f="18880">7</offsets></xref><offsets xml_i="27344" xml_f="27852" txt_i="18880" txt_f="19388">]. Only a non-significant effect was seen on T2 lesion load, and the frequency of gadolinium-enhancing lesions was not assessed. In secondary analyses, disease progression appeared to be delayed, while there was no effect on the relapse rate. In secondary-progressive MS, repeated courses of IV-MP every eight weeks delayed the time to confirmed disease progression in a dose-dependant fashion, while failing with respect to the proportion of patients with disease progression (the primary outcome measure) [</offsets><xref ref-type="bibr" rid="B6"><offsets xml_i="27883" xml_f="27884" txt_i="19388" txt_f="19389">6</offsets></xref><offsets xml_i="27891" xml_f="28079" txt_i="19389" txt_f="19577">]. MRI was not performed in that trial. IV-MP has previously been shown to rapidly, though transiently reduce gadolinium enhancement in MS, when given for several days for acute relapses [</offsets><xref ref-type="bibr" rid="B8"><offsets xml_i="28110" xml_f="28111" txt_i="19577" txt_f="19578">8</offsets></xref><offsets xml_i="28118" xml_f="28119" txt_i="19578" txt_f="19579">-</offsets><xref ref-type="bibr" rid="B10"><offsets xml_i="28151" xml_f="28153" txt_i="19579" txt_f="19581">10</offsets></xref><offsets xml_i="28160" xml_f="28161" txt_i="19581" txt_f="19582">,</offsets><xref ref-type="bibr" rid="B23"><offsets xml_i="28193" xml_f="28195" txt_i="19582" txt_f="19584">23</offsets></xref><offsets xml_i="28202" xml_f="28379" txt_i="19584" txt_f="19761">]. Our study suggests that in the absence of relapse, a single infusion has a similar effect, and that the reduction of inflammatory activity can be extended by repeat infusion.</offsets></p><p><offsets xml_i="28386" xml_f="28830" txt_i="19762" txt_f="20206">With the single cross-over study protocol and the selection of patients based on a minimum number of enhancing lesions during the baseline period, a potential alternative explanation for the reduction of enhancing lesions would be "regression to the mean". The mean number of active lesions during the baseline period is comparable to some earlier studies using the same single cross-over design as in this study, while it was lower in others [</offsets><xref ref-type="bibr" rid="B24"><offsets xml_i="28862" xml_f="28864" txt_i="20206" txt_f="20208">24</offsets></xref><offsets xml_i="28871" xml_f="28872" txt_i="20208" txt_f="20209">-</offsets><xref ref-type="bibr" rid="B27"><offsets xml_i="28904" xml_f="28906" txt_i="20209" txt_f="20211">27</offsets></xref><offsets xml_i="28913" xml_f="29248" txt_i="20211" txt_f="20546">]. Comparison to a pooled dataset showed that inflammatory activity in our patients was high, but not exceptional (see below). In addition, the sharpest decline in the slope of the regression curve occurs between months 6 and 7, concomitant with the start of treatment. These factors make pure "regression to the mean" highly unlikely.</offsets></p><p><offsets xml_i="29255" xml_f="29755" txt_i="20547" txt_f="21047">In an effort to estimate the magnitude of regression to the mean, we extracted a comparison group from a large database of patients collected from various centers, who had undergone regular contrast enhanced MRI over twelve months as placebo patients of clinical trials. This comparison group of 83 patients, selected by clinical and imaging criteria equivalent to ours, had a mean frequency of Gd-enhancing lesions which is higher than would be expected for an unselected population of MS patients [</offsets><xref ref-type="bibr" rid="B28"><offsets xml_i="29787" xml_f="29789" txt_i="21047" txt_f="21049">28</offsets></xref><offsets xml_i="29796" xml_f="30494" txt_i="21049" txt_f="21747">]. Of note, this number tends to even underestimate the true frequency of new lesions, since not all patients had strictly monthly scans, and some new lesions with a short duration of enhancement may have been missed. By natural history alone, the mean number of new enhancing lesions in the comparison group changed over a wide range during the following six months, resulting in a non-significant reduction by 6.4% for the entire group. Thus, many patients selected for a minimum frequency of active lesions appear to continue on that above-average inflammatory activity, and at least over a subsequent six-month period, "regression" to mean values as described in unselected MS patient cohorts [</offsets><xref ref-type="bibr" rid="B28"><offsets xml_i="30526" xml_f="30528" txt_i="21747" txt_f="21749">28</offsets></xref><offsets xml_i="30535" xml_f="30834" txt_i="21749" txt_f="22048">] applies to the selected group only on a relatively limited scale. Importantly, even if we conservatively assume a more pronounced effect of regression to the mean in our patients, we can still conclude that monthly methylprednisolone contributed far more to the reduction of inflammatory activity.</offsets></p><sec><title><offsets xml_i="30850" xml_f="30884" txt_i="22049" txt_f="22083">Corticosteroids and T2 lesion load</offsets></title><p><xref ref-type="bibr" rid="B29"><offsets xml_i="30927" xml_f="30929" txt_i="22084" txt_f="22086">29</offsets></xref><offsets xml_i="30936" xml_f="30937" txt_i="22086" txt_f="22087">,</offsets><xref ref-type="bibr" rid="B30"><offsets xml_i="30969" xml_f="30971" txt_i="22087" txt_f="22089">30</offsets></xref><offsets xml_i="30978" xml_f="31172" txt_i="22089" txt_f="22283">], can be largely excluded because (i) no accompanying brain volume decrease was seen and (ii) serial MP infusions led to a cumulative decrease of T2 lesion volume. Previous studies over short [</offsets><xref ref-type="bibr" rid="B23"><offsets xml_i="31204" xml_f="31206" txt_i="22283" txt_f="22285">23</offsets></xref><offsets xml_i="31213" xml_f="31214" txt_i="22285" txt_f="22286">,</offsets><xref ref-type="bibr" rid="B30"><offsets xml_i="31246" xml_f="31248" txt_i="22286" txt_f="22288">30</offsets></xref><offsets xml_i="31255" xml_f="31256" txt_i="22288" txt_f="22289">,</offsets><xref ref-type="bibr" rid="B31"><offsets xml_i="31288" xml_f="31290" txt_i="22289" txt_f="22291">31</offsets></xref><offsets xml_i="31297" xml_f="31319" txt_i="22291" txt_f="22313">] and longer periods [</offsets><xref ref-type="bibr" rid="B7"><offsets xml_i="31350" xml_f="31351" txt_i="22313" txt_f="22314">7</offsets></xref><offsets xml_i="31358" xml_f="31461" txt_i="22314" txt_f="22417">] failed to demonstrate changes in T2 lesion load. In short-term studies of MP in acute exacerbations [</offsets><xref ref-type="bibr" rid="B23"><offsets xml_i="31493" xml_f="31495" txt_i="22417" txt_f="22419">23</offsets></xref><offsets xml_i="31502" xml_f="31503" txt_i="22419" txt_f="22420">,</offsets><xref ref-type="bibr" rid="B30"><offsets xml_i="31535" xml_f="31537" txt_i="22420" txt_f="22422">30</offsets></xref><offsets xml_i="31544" xml_f="31545" txt_i="22422" txt_f="22423">,</offsets><xref ref-type="bibr" rid="B31"><offsets xml_i="31577" xml_f="31579" txt_i="22423" txt_f="22425">31</offsets></xref><offsets xml_i="31586" xml_f="31910" txt_i="22425" txt_f="22749">], an anti-edematous effect can be expected to be particularly prominent, while our patients received a single infusion in the absence of acute relapse. Edema resolution thus appears to contribute less to this change in T2 signal than other histological changes (extent of gliosis, macrophage infiltration or remyelination).</offsets></p></sec><sec><title><offsets xml_i="31932" xml_f="31985" txt_i="22751" txt_f="22804">The role of prolactin during corticosteroid treatment</offsets></title><p><offsets xml_i="31996" xml_f="32335" txt_i="22805" txt_f="23144">The parallel time-course of prolactin and Gd-enhancing lesions during both baseline and treatment with repeated steroid infusions is intriguing with respect to a possible role of prolactin in the autoimmune process. Elevated plasma levels of prolactin have been described in MS relapse, with return to normal concentrations upon recovery [</offsets><xref ref-type="bibr" rid="B16"><offsets xml_i="32367" xml_f="32369" txt_i="23144" txt_f="23146">16</offsets></xref><offsets xml_i="32376" xml_f="32484" txt_i="23146" txt_f="23254">]. In other studies, plasma levels were higher in MS patients than in controls, albeit in the normal range [</offsets><xref ref-type="bibr" rid="B32"><offsets xml_i="32516" xml_f="32518" txt_i="23254" txt_f="23256">32</offsets></xref><offsets xml_i="32525" xml_f="32539" txt_i="23256" txt_f="23270">], or normal [</offsets><xref ref-type="bibr" rid="B33"><offsets xml_i="32571" xml_f="32573" txt_i="23270" txt_f="23272">33</offsets></xref><offsets xml_i="32580" xml_f="32581" txt_i="23272" txt_f="23273">,</offsets><xref ref-type="bibr" rid="B34"><offsets xml_i="32613" xml_f="32615" txt_i="23273" txt_f="23275">34</offsets></xref><offsets xml_i="32622" xml_f="32708" txt_i="23275" txt_f="23361">]. While the role of prolactin in human immune function is a matter of debate (e.g., [</offsets><xref ref-type="bibr" rid="B35"><offsets xml_i="32740" xml_f="32742" txt_i="23361" txt_f="23363">35</offsets></xref><offsets xml_i="32749" xml_f="32750" txt_i="23363" txt_f="23364">,</offsets><xref ref-type="bibr" rid="B36"><offsets xml_i="32782" xml_f="32784" txt_i="23364" txt_f="23366">36</offsets></xref><offsets xml_i="32791" xml_f="32873" txt_i="23366" txt_f="23448">]), experimental data appear to support an immunostimulatory effect of prolactin [</offsets><xref ref-type="bibr" rid="B37"><offsets xml_i="32905" xml_f="32907" txt_i="23448" txt_f="23450">37</offsets></xref><offsets xml_i="32914" xml_f="32915" txt_i="23450" txt_f="23451">-</offsets><xref ref-type="bibr" rid="B39"><offsets xml_i="32947" xml_f="32949" txt_i="23451" txt_f="23453">39</offsets></xref><offsets xml_i="32956" xml_f="33079" txt_i="23453" txt_f="23576">]. Elevated levels of endogenous or therapeutic glucocorticoids are associated with clinically relevant immunosuppression [</offsets><xref ref-type="bibr" rid="B40"><offsets xml_i="33111" xml_f="33113" txt_i="23576" txt_f="23578">40</offsets></xref><offsets xml_i="33120" xml_f="33217" txt_i="23578" txt_f="23675">] through several mechanisms, and at the same time reduce expression and secretion of prolactin [</offsets><xref ref-type="bibr" rid="B41"><offsets xml_i="33249" xml_f="33251" txt_i="23675" txt_f="23677">41</offsets></xref><offsets xml_i="33258" xml_f="33259" txt_i="23677" txt_f="23678">,</offsets><xref ref-type="bibr" rid="B42"><offsets xml_i="33291" xml_f="33293" txt_i="23678" txt_f="23680">42</offsets></xref><offsets xml_i="33300" xml_f="33704" txt_i="23680" txt_f="24084">]. A mere side-effect of steroid administration is unlikely given the significant cross-correlation with enhancing lesions during the baseline period. It remains to be determined if lower prolactin during treatment contributes to the reduction of inflammatory disease activity, or if blunted inflammation leads to a reduced level of general stressors which non-specifically stimulate prolactin secretion.</offsets></p></sec><sec><title><offsets xml_i="33726" xml_f="33753" txt_i="24086" txt_f="24113">Measures of immune function</offsets></title><p><offsets xml_i="33764" xml_f="34226" txt_i="24114" txt_f="24576">The panel of immunological analyses performed in this study was chosen based on specific hypotheses rather than being designed as a comprehensive immunological assessment of pulsed corticosteroid treatment. Focusing on these selected parameters, we did not observe significant changes associated with monthly IV-MP. However, this does not argue against a lasting immunological effect of pulsed steroids, which potentially could be measured by additional markers.</offsets></p></sec><sec><title><offsets xml_i="34248" xml_f="34299" txt_i="24578" txt_f="24629">Clinical prospects for pulsed glucocorticoids in MS</offsets></title><p><offsets xml_i="34310" xml_f="34719" txt_i="24630" txt_f="25039">We are aware that the small number of patients studied and lack of long-term data prohibit direct clinical consequences from this study and we do not suggest pulsed corticosteroids as routine treatment. However, our study demonstrates an anti-inflammatory effect with almost no relevant short-term side effects, and no indication for adrenal insufficiency or osteopenia, in line with recently published data [</offsets><xref ref-type="bibr" rid="B43"><offsets xml_i="34751" xml_f="34753" txt_i="25039" txt_f="25041">43</offsets></xref><offsets xml_i="34760" xml_f="34806" txt_i="25041" txt_f="25087">]. Our results thus support further research [</offsets><xref ref-type="bibr" rid="B17"><offsets xml_i="34838" xml_f="34840" txt_i="25087" txt_f="25089">17</offsets></xref><offsets xml_i="34847" xml_f="34849" txt_i="25089" txt_f="25091">].</offsets></p></sec></sec><sec><title><offsets xml_i="34877" xml_f="34887" txt_i="25094" txt_f="25104">Conclusion</offsets></title><p><offsets xml_i="34898" xml_f="35211" txt_i="25105" txt_f="25418">In relapsing-remitting multiple sclerosis, once-monthly IV methylprednisolone reduces inflammatory activity as measured by the best currently available surrogate measure (high-frequency contrast enhanced brain MRI). The effect is sufficient to support further study of this approach in certain groups of patients.</offsets></p></sec><sec><title><offsets xml_i="35233" xml_f="35252" txt_i="25420" txt_f="25439">Competing interests</offsets></title><p><offsets xml_i="35263" xml_f="35323" txt_i="25440" txt_f="25500">The author(s) declare that they have no competing interests.</offsets></p></sec><sec><title><offsets xml_i="35345" xml_f="35367" txt_i="25502" txt_f="25524">Authors' contributions</offsets></title><p><offsets xml_i="35378" xml_f="36232" txt_i="25525" txt_f="26379">FTB, TK: Trial design, drafting of ethics submission; general organization; data collection and analysis; initial drafting of manuscript; DPA: Trial design, MRI data acquisition and analysis; participated in initial drafting of manuscript; FTB, TK, MS, CT: patient selection, information, enrollment, clinical follow-up, endocrinological testing, oversight of patient safety; ES: Assessment of MRI imaging quality, blinded MRI data analysis; MB, AW: Volumetric MRI analysis (T2-LL and BFV); AY: Trial design (Statistics), data analysis; UH, MD: Extraction, verification and statistical analysis of comparison group data (SLC database); FH: Assessment and interpretation of neuroendocrine testing; MU, FW: Laboratory analyses and interpretation of hormone, cytokine and adhesion molecule concentrations. All authors read and approved the final manuscript.</offsets></p></sec><sec><title><offsets xml_i="36254" xml_f="36277" txt_i="26381" txt_f="26404">Pre-publication history</offsets></title><p><offsets xml_i="36288" xml_f="36352" txt_i="26405" txt_f="26469">The pre-publication history for this paper can be accessed here:</offsets></p><p><ext-link ext-link-type="uri" xlink:href="http://www.biomedcentral.com/1471-2377/6/19/prepub"></ext-link></p></sec></body><back><ack><sec><title>Acknowledgements</title><p>We would like to thank Elisabeth Kappelmann and Heike Staufer for continuous technical support, Johannes Behrends for installation of the deployed segmentation software, and Andrea Graml for statistical programming. The Sylvia Lawry Centre for Multiple Sclerosis Research is indebted to many academic centres and pharmaceutical companies who have generously donated their data. A list of these data donors can be found at the link provided as referenece [<xref ref-type="bibr" rid="B44">44</xref>].</p></sec></ack><ref-list><ref id="B1"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Milligan</surname><given-names>NM</given-names></name><name><surname>Newcombe</surname><given-names>R</given-names></name><name><surname>Compston</surname><given-names>DA</given-names></name></person-group><article-title>A double-blind controlled trial of high dose methylprednisolone in patients with multiple sclerosis: 1. Clinical effects</article-title><source>J Neurol Neurosurg Psychiatry</source><year>1987</year><volume>50</volume><fpage>511</fpage><lpage>6</lpage><pub-id pub-id-type="pmid">3295122</pub-id></citation></ref><ref id="B2"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Thompson</surname><given-names>AJ</given-names></name><name><surname>Kennard</surname><given-names>C</given-names></name><name><surname>Swash</surname><given-names>M</given-names></name><name><surname>Summers</surname><given-names>B</given-names></name><name><surname>Yuill</surname><given-names>GM</given-names></name><name><surname>Shepherd</surname><given-names>DI</given-names></name><name><surname>Roche</surname><given-names>S</given-names></name><name><surname>Perkin</surname><given-names>GD</given-names></name><name><surname>Loizou</surname><given-names>LA</given-names></name><name><surname>Ferner</surname><given-names>R</given-names></name><name><surname>Hughes</surname><given-names>RAC</given-names></name><name><surname>Thompson</surname><given-names>M</given-names></name><name><surname>Hand</surname><given-names>J</given-names></name></person-group><article-title>Relative efficacy of intravenous methylprednisolone and ACTH in the treatment of acute relapse in MS</article-title><source>Neurology</source><year>1989</year><volume>39</volume><fpage>969</fpage><lpage>971</lpage><pub-id pub-id-type="pmid">2544829</pub-id></citation></ref><ref id="B3"><citation citation-type="journal"><person-group person-group-type="author"><collab>Optic Neuritis Study Group</collab></person-group><article-title>The 5-year risk of MS after optic neuritis. Experience of the optic neuritis treatment trial</article-title><source>Neurology</source><year>1997</year><volume>49</volume><fpage>1404</fpage><lpage>1413</lpage><pub-id pub-id-type="pmid">9371930</pub-id></citation></ref><ref id="B4"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Beck</surname><given-names>RW</given-names></name><name><surname>Trobe</surname><given-names>JD</given-names></name><name><surname>Moke</surname><given-names>PS</given-names></name><name><surname>Gal</surname><given-names>RL</given-names></name><name><surname>Xing</surname><given-names>D</given-names></name><name><surname>Bhatti</surname><given-names>MT</given-names></name><name><surname>Brodsky</surname><given-names>MC</given-names></name><name><surname>Buckley</surname><given-names>EG</given-names></name><name><surname>Chrousos</surname><given-names>GA</given-names></name><name><surname>Corbett</surname><given-names>J</given-names></name><name><surname>Eggenberger</surname><given-names>E</given-names></name><name><surname>Goodwin</surname><given-names>JA</given-names></name><name><surname>Katz</surname><given-names>B</given-names></name><name><surname>Kaufman</surname><given-names>DI</given-names></name><name><surname>Keltner</surname><given-names>JL</given-names></name><name><surname>Kupersmith</surname><given-names>MJ</given-names></name><name><surname>Miller</surname><given-names>NR</given-names></name><name><surname>Nazarian</surname><given-names>S</given-names></name><name><surname>Orengo-Nania</surname><given-names>S</given-names></name><name><surname>Savino</surname><given-names>PJ</given-names></name><name><surname>Shults</surname><given-names>WT</given-names></name><name><surname>Smith</surname><given-names>CH</given-names></name><name><surname>Wall</surname><given-names>M</given-names></name></person-group><article-title>High- and low-risk profiles for the development of multiple sclerosis within 10 years after optic neuritis: experience of the optic neuritis treatment trial</article-title><source>Arch Ophthalmol</source><year>2003</year><volume>121</volume><fpage>944</fpage><lpage>949</lpage><pub-id pub-id-type="pmid">12860795</pub-id><pub-id pub-id-type="doi">10.1001/archopht.121.7.944</pub-id></citation></ref><ref id="B5"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kaufman</surname><given-names>DI</given-names></name><name><surname>Trobe</surname><given-names>JD</given-names></name><name><surname>Eggenberger</surname><given-names>ER</given-names></name><name><surname>Whitaker</surname><given-names>JN</given-names></name></person-group><article-title>Practice parameter: The role of corticosteroids in the management of acute monosymptomatic optic neuritis: Report of the Quality Standards Subcommittee of the American Academy of Neurology</article-title><source>Neurology</source><year>2000</year><volume>54</volume><fpage>2039</fpage><lpage>2044</lpage><pub-id pub-id-type="pmid">10851360</pub-id></citation></ref><ref id="B6"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Goodkin</surname><given-names>DE</given-names></name><name><surname>Kinkel</surname><given-names>RP</given-names></name><name><surname>Weinstock-Guttman</surname><given-names>B</given-names></name><name><surname>VanderBrug-Medendorp</surname><given-names>S</given-names></name><name><surname>Secic</surname><given-names>M</given-names></name><name><surname>Gogol</surname><given-names>D</given-names></name><name><surname>Perryman</surname><given-names>JE</given-names></name><name><surname>Uccelli</surname><given-names>MM</given-names></name><name><surname>Neilley</surname><given-names>L</given-names></name></person-group><article-title>A phase II study of i.v. methylprednisolone in secondary-progressive multiple sclerosis</article-title><source>Neurology</source><year>1998</year><volume>51</volume><fpage>239</fpage><lpage>45</lpage><pub-id pub-id-type="pmid">9674809</pub-id><pub-id pub-id-type="doi">10.1159/000006541</pub-id></citation></ref><ref id="B7"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Zivadinov</surname><given-names>R</given-names></name><name><surname>Rudick</surname><given-names>RA</given-names></name><name><surname>De Masi</surname><given-names>R</given-names></name><name><surname>Nasuelli</surname><given-names>D</given-names></name><name><surname>Ukmar</surname><given-names>M</given-names></name><name><surname>Pozzi-Mucelli</surname><given-names>RS</given-names></name><name><surname>Grop</surname><given-names>A</given-names></name><name><surname>Cazzato</surname><given-names>G</given-names></name><name><surname>Zorzon</surname><given-names>M</given-names></name></person-group><article-title>Effects of IV methylprednisolone on brain atrophy in relapsing-remitting MS</article-title><source>Neurology</source><year>2001</year><volume>57</volume><fpage>1239</fpage><lpage>1247</lpage><pub-id pub-id-type="pmid">11591843</pub-id></citation></ref><ref id="B8"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Miller</surname><given-names>DH</given-names></name><name><surname>Thompson</surname><given-names>AJ</given-names></name><name><surname>Morrissey</surname><given-names>SP</given-names></name><name><surname>MacManus</surname><given-names>DG</given-names></name><name><surname>Moore</surname><given-names>SG</given-names></name><name><surname>Kendall</surname><given-names>BE</given-names></name><name><surname>Moseley</surname><given-names>IF</given-names></name><name><surname>McDonald</surname><given-names>WI</given-names></name></person-group><article-title>High dose steroids in acute relapses of multiple sclerosis: MRI evidence for a possible mechanism of therapeutic effect</article-title><source>J Neurol Neurosurg Psychiatry</source><year>1992</year><volume>55</volume><fpage>450</fpage><lpage>453</lpage><pub-id pub-id-type="pmid">1619410</pub-id></citation></ref><ref id="B9"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Burnham</surname><given-names>JA</given-names></name><name><surname>Wright</surname><given-names>RR</given-names></name><name><surname>Dreisbach</surname><given-names>J</given-names></name><name><surname>Murray</surname><given-names>RS</given-names></name></person-group><article-title>The effect of high-dose steroids on MRI gadolinium enhancement in acute demyelinating lesions</article-title><source>Neurology</source><year>1991</year><volume>41</volume><fpage>1349</fpage><lpage>1354</lpage><pub-id pub-id-type="pmid">1891079</pub-id></citation></ref><ref id="B10"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Barkhof</surname><given-names>F</given-names></name><name><surname>Hommes</surname><given-names>OR</given-names></name><name><surname>Scheltens</surname><given-names>P</given-names></name><name><surname>Valk</surname><given-names>J</given-names></name></person-group><article-title>Quantitative MRI changes in gadolinium-DTPA enhancement after high-dose intravenous methylprednisolone in multiple sclerosis</article-title><source>Neurology</source><year>1991</year><volume>41</volume><fpage>1219</fpage><lpage>1222</lpage><pub-id pub-id-type="pmid">1866009</pub-id></citation></ref><ref id="B11"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Gold</surname><given-names>R</given-names></name><name><surname>Buttgereit</surname><given-names>F</given-names></name><name><surname>Toyka</surname><given-names>KV</given-names></name></person-group><article-title>Mechanism of action of glucocorticosteroid hormones: possible implications for therapy of neuroimmunological disorders</article-title><source>J Neuroimmunol</source><year>2001</year><volume>117</volume><fpage>1</fpage><lpage>8</lpage><pub-id pub-id-type="pmid">11430999</pub-id><pub-id pub-id-type="doi">10.1016/S0165-5728(01)00330-7</pub-id></citation></ref><ref id="B12"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Webster</surname><given-names>JI</given-names></name><name><surname>Tonelli</surname><given-names>L</given-names></name><name><surname>Sternberg</surname><given-names>EM</given-names></name></person-group><article-title>Neuroendocrine regulation of immunity</article-title><source>Annu Rev Immunol</source><year>2002</year><volume>20</volume><fpage>125</fpage><lpage>163</lpage><pub-id pub-id-type="pmid">11861600</pub-id><pub-id pub-id-type="doi">10.1146/annurev.immunol.20.082401.104914</pub-id></citation></ref><ref id="B13"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Then Bergh</surname><given-names>F</given-names></name><name><surname>Kümpfel</surname><given-names>T</given-names></name><name><surname>Trenkwalder</surname><given-names>C</given-names></name><name><surname>Rupprecht</surname><given-names>R</given-names></name><name><surname>Holsboer</surname><given-names>F</given-names></name></person-group><article-title>Dysregulation of the hypothalamo-pituitary-adrenal axis is related to the clinical course of MS</article-title><source>Neurology</source><year>1999</year><volume>53</volume><fpage>772</fpage><lpage>777</lpage><pub-id pub-id-type="pmid">10489039</pub-id></citation></ref><ref id="B14"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Schumann</surname><given-names>EM</given-names></name><name><surname>Kümpfel</surname><given-names>T</given-names></name><name><surname>Then Bergh</surname><given-names>F</given-names></name><name><surname>Trenkwalder</surname><given-names>C</given-names></name><name><surname>Holsboer</surname><given-names>F</given-names></name><name><surname>Auer</surname><given-names>DP</given-names></name></person-group><article-title>Activity of the hypothalamic-pituitary-adrenal axis in multiple sclerosis: correlations with gadolinium-enhancing lesions and ventricular volume</article-title><source>Ann Neurol</source><year>2002</year><volume>51</volume><fpage>763</fpage><lpage>767</lpage><pub-id pub-id-type="pmid">12112083</pub-id><pub-id pub-id-type="doi">10.1002/ana.10187</pub-id></citation></ref><ref id="B15"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Michelson</surname><given-names>D</given-names></name><name><surname>Stone</surname><given-names>L</given-names></name><name><surname>Galliven</surname><given-names>E</given-names></name><name><surname>Magiakou</surname><given-names>MA</given-names></name><name><surname>Chrousos</surname><given-names>GP</given-names></name><name><surname>Sternberg</surname><given-names>EM</given-names></name><name><surname>Gold</surname><given-names>PW</given-names></name></person-group><article-title>Multiple sclerosis is associated with alterations in hypothalamic-pituitary-adrenal axis function</article-title><source>J Clin Endocrinol Metab</source><year>1994</year><volume>79</volume><fpage>848</fpage><lpage>853</lpage><pub-id pub-id-type="pmid">8077372</pub-id><pub-id pub-id-type="doi">10.1210/jc.79.3.848</pub-id></citation></ref><ref id="B16"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kira</surname><given-names>J</given-names></name><name><surname>Harada</surname><given-names>M</given-names></name><name><surname>Yamaguchi</surname><given-names>Y</given-names></name><name><surname>Shida</surname><given-names>N</given-names></name><name><surname>Goto</surname><given-names>I</given-names></name></person-group><article-title>Hyperprolactinemia in multiple sclerosis</article-title><source>J Neurol Sci</source><year>1991</year><volume>102</volume><fpage>61</fpage><lpage>66</lpage><pub-id pub-id-type="pmid">1906932</pub-id><pub-id pub-id-type="doi">10.1016/0022-510X(91)90094-N</pub-id></citation></ref><ref id="B17"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Miller</surname><given-names>DH</given-names></name><name><surname>Albert</surname><given-names>PS</given-names></name><name><surname>Barkhof</surname><given-names>F</given-names></name><name><surname>Francis</surname><given-names>G</given-names></name><name><surname>Frank</surname><given-names>JA</given-names></name><name><surname>Hodgkinson</surname><given-names>S</given-names></name><name><surname>Lublin</surname><given-names>FD</given-names></name><name><surname>Paty</surname><given-names>DW</given-names></name><name><surname>Reingold</surname><given-names>SC</given-names></name><name><surname>Simon</surname><given-names>J</given-names></name></person-group><article-title>Guidelines for the use of magnetic resonance techniques in monitoring the treatment of multiple sclerosis. US National MS Society Task Force</article-title><source>Ann Neurol</source><year>1996</year><volume>39</volume><fpage>6</fpage><lpage>16</lpage><pub-id pub-id-type="pmid">8572668</pub-id><pub-id pub-id-type="doi">10.1002/ana.410390104</pub-id></citation></ref><ref id="B18"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Sormani</surname><given-names>MP</given-names></name><name><surname>Miller</surname><given-names>DH</given-names></name><name><surname>Comi</surname><given-names>G</given-names></name><name><surname>Barkhof</surname><given-names>F</given-names></name><name><surname>Rovaris</surname><given-names>M</given-names></name><name><surname>Bruzzi</surname><given-names>P</given-names></name><name><surname>Filippi</surname><given-names>M</given-names></name></person-group><article-title>Clinical trials of multiple sclerosis monitored with enhanced MRI: new sample size calculations based on large data sets</article-title><source>J Neurol Neurosurg Psychiatry</source><year>2001</year><volume>70</volume><fpage>494</fpage><lpage>499</lpage><pub-id pub-id-type="pmid">11254773</pub-id><pub-id pub-id-type="doi">10.1136/jnnp.70.4.494</pub-id></citation></ref><ref id="B19"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Poser</surname><given-names>CM</given-names></name><name><surname>Paty</surname><given-names>DW</given-names></name><name><surname>Scheinberg</surname><given-names>L</given-names></name><name><surname>McDonald</surname><given-names>WI</given-names></name><name><surname>Davis</surname><given-names>FA</given-names></name><name><surname>Ebers</surname><given-names>GC</given-names></name><name><surname>Johnson</surname><given-names>KP</given-names></name><name><surname>Sibley</surname><given-names>WA</given-names></name><name><surname>Silberberg</surname><given-names>DH</given-names></name><name><surname>Tourtelotte</surname><given-names>WW</given-names></name></person-group><article-title>New diagnostic criteria for multiple sclerosis: guidelines for research protocols</article-title><source>Ann Neurol</source><year>1983</year><volume>13</volume><fpage>227</fpage><lpage>231</lpage><pub-id pub-id-type="pmid">6847134</pub-id><pub-id pub-id-type="doi">10.1002/ana.410130302</pub-id></citation></ref><ref id="B20"><citation citation-type="book"><person-group person-group-type="author"><name><surname>Wismüller</surname><given-names>A</given-names></name><name><surname>Behrends</surname><given-names>J</given-names></name><name><surname>Lange</surname><given-names>O</given-names></name><name><surname>Jukic</surname><given-names>M</given-names></name><name><surname>Hahn</surname><given-names>K</given-names></name><name><surname>Reiser</surname><given-names>MF</given-names></name><name><surname>Auer</surname><given-names>DP</given-names></name></person-group><person-group person-group-type="editor"><name><surname>Wittenberg T</surname></name></person-group><article-title>High-precision computer-assisted segmentation of multispectral data sets in patients with multiple sclerosis by a flexible machine learning image analysis approach</article-title><source>Bildverarbeitung für die Medizin 2003</source><year>2003</year><publisher-name>Berlin: Springer Verlag</publisher-name><fpage>403</fpage><lpage>407</lpage></citation></ref><ref id="B21"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ge</surname><given-names>Y</given-names></name><name><surname>Grossman</surname><given-names>RI</given-names></name><name><surname>Udupa</surname><given-names>JK</given-names></name><name><surname>Wei</surname><given-names>L</given-names></name><name><surname>Mannon</surname><given-names>LJ</given-names></name><name><surname>Polansky</surname><given-names>M</given-names></name><name><surname>Kolson</surname><given-names>DL</given-names></name></person-group><article-title>Brain atrophy in relapsing-remitting multiple sclerosis and secondary progressive multiple sclerosis: longitudinal quantitative analysis</article-title><source>Radiology</source><year>2000</year><volume>214</volume><fpage>665</fpage><lpage>670</lpage><pub-id pub-id-type="pmid">10715027</pub-id></citation></ref><ref id="B22"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kurtzke</surname><given-names>JF</given-names></name></person-group><article-title>Rating neurologic impairment in multiple sclerosis: An expanded disability status scale (EDSS)</article-title><source>Neurology</source><year>1983</year><volume>33</volume><fpage>1444</fpage><lpage>1452</lpage><pub-id pub-id-type="pmid">6685237</pub-id></citation></ref><ref id="B23"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Barkhof</surname><given-names>F</given-names></name><name><surname>Tas</surname><given-names>M</given-names></name><name><surname>Frequin</surname><given-names>ST</given-names></name><name><surname>Scheltens</surname><given-names>P</given-names></name><name><surname>Hommes</surname><given-names>OR</given-names></name><name><surname>Nauta</surname><given-names>JJ</given-names></name><name><surname>Valk</surname><given-names>J</given-names></name></person-group><article-title>Limited duration of the effect of methylprednisolone on changes on MRI in multiple sclerosis</article-title><source>Neuroradiology</source><year>1994</year><volume>36</volume><fpage>382</fpage><lpage>387</lpage><pub-id pub-id-type="pmid">7936181</pub-id><pub-id pub-id-type="doi">10.1007/BF00612124</pub-id></citation></ref><ref id="B24"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Stone</surname><given-names>LA</given-names></name><name><surname>Frank</surname><given-names>JA</given-names></name><name><surname>Albert</surname><given-names>PS</given-names></name><name><surname>Bash</surname><given-names>C</given-names></name><name><surname>Smith</surname><given-names>ME</given-names></name><name><surname>Maloni</surname><given-names>H</given-names></name><name><surname>McFarland</surname><given-names>HF</given-names></name></person-group><article-title>The effect of interferon-beta on blood-brain barrier disruptions demonstrated by contrast-enhanced magnetic resonance imaging in relapsing-remitting multiple sclerosis</article-title><source>Ann Neurol</source><year>1995</year><volume>37</volume><fpage>611</fpage><lpage>619</lpage><pub-id pub-id-type="pmid">7755356</pub-id><pub-id pub-id-type="doi">10.1002/ana.410370511</pub-id></citation></ref><ref id="B25"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Waubant</surname><given-names>E</given-names></name><name><surname>Goodkin</surname><given-names>DE</given-names></name><name><surname>Sloan</surname><given-names>R</given-names></name><name><surname>Andersson</surname><given-names>PB</given-names></name></person-group><article-title>A pilot study of MRI activity before and during interferon beta-1a therapy</article-title><source>Neurology</source><year>1999</year><volume>53</volume><fpage>874</fpage><lpage>876</lpage><pub-id pub-id-type="pmid">10489060</pub-id></citation></ref><ref id="B26"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Filippi</surname><given-names>M</given-names></name><name><surname>Rovaris</surname><given-names>M</given-names></name><name><surname>Capra</surname><given-names>R</given-names></name><name><surname>Gasperini</surname><given-names>C</given-names></name><name><surname>Prandini</surname><given-names>F</given-names></name><name><surname>Martinelli</surname><given-names>V</given-names></name><name><surname>Horsfield</surname><given-names>MA</given-names></name><name><surname>Bastianello</surname><given-names>S</given-names></name><name><surname>Sormani</surname><given-names>MP</given-names></name><name><surname>Pozzilli</surname><given-names>C</given-names></name><name><surname>Comi</surname><given-names>G</given-names></name></person-group><article-title>Interferon beta treatment for multiple sclerosis has a graduated effect on MRI enhancing lesions according to their size and pathology</article-title><source>J Neurol Neurosurg Psychiatry</source><year>1999</year><volume>67</volume><fpage>386</fpage><lpage>389</lpage><pub-id pub-id-type="pmid">10449565</pub-id></citation></ref><ref id="B27"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Mancardi</surname><given-names>GL</given-names></name><name><surname>Sardanelli</surname><given-names>F</given-names></name><name><surname>Parodi</surname><given-names>RC</given-names></name><name><surname>Melani</surname><given-names>E</given-names></name><name><surname>Capello</surname><given-names>E</given-names></name><name><surname>Inglese</surname><given-names>M</given-names></name><name><surname>Ferrari</surname><given-names>A</given-names></name><name><surname>Sormani</surname><given-names>MP</given-names></name><name><surname>Ottonello</surname><given-names>C</given-names></name><name><surname>Levrero</surname><given-names>F</given-names></name><name><surname>Uccelli</surname><given-names>A</given-names></name><name><surname>Bruzzi</surname><given-names>P</given-names></name></person-group><article-title>Effect of copolymer-1 on serial gadolinium-enhanced MRI in relapsing remitting multiple sclerosis</article-title><source>Neurology</source><year>1998</year><volume>50</volume><fpage>1127</fpage><lpage>1133</lpage><pub-id pub-id-type="pmid">9566406</pub-id></citation></ref><ref id="B28"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kappos</surname><given-names>L</given-names></name><name><surname>Moeri</surname><given-names>D</given-names></name><name><surname>Radue</surname><given-names>EW</given-names></name><name><surname>Schoetzau</surname><given-names>A</given-names></name><name><surname>Schweikert</surname><given-names>K</given-names></name><name><surname>Barkhof</surname><given-names>F</given-names></name><name><surname>Miller</surname><given-names>D</given-names></name><name><surname>Guttmann</surname><given-names>CR</given-names></name><name><surname>Weiner</surname><given-names>HL</given-names></name><name><surname>Gasperini</surname><given-names>C</given-names></name><name><surname>Filippi</surname><given-names>M</given-names></name></person-group><article-title>Predictive value of gadolinium-enhanced magnetic resonance imaging for relapse rate and changes in disability or impairment in multiple sclerosis: a meta-analysis. Gadolinium MRI Meta-analysis Group</article-title><source>Lancet</source><year>1999</year><volume>353</volume><fpage>964</fpage><lpage>9</lpage><pub-id pub-id-type="pmid">10459905</pub-id><pub-id pub-id-type="doi">10.1016/S0140-6736(98)03053-0</pub-id></citation></ref><ref id="B29"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hoogervorst</surname><given-names>EL</given-names></name><name><surname>Polman</surname><given-names>CH</given-names></name><name><surname>Barkhof</surname><given-names>F</given-names></name></person-group><article-title>Cerebral volume changes in multiple sclerosis patients treated with high-dose intravenous methylprednisolone</article-title><source>Mult Scler</source><year></year><volume>8</volume><fpage>415</fpage><lpage>419</lpage><pub-id pub-id-type="pmid">12356209</pub-id><pub-id pub-id-type="doi">10.1191/1352458502ms838oa</pub-id></citation></ref><ref id="B30"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Rao</surname><given-names>AB</given-names></name><name><surname>Richert</surname><given-names>N</given-names></name><name><surname>Howard</surname><given-names>T</given-names></name><name><surname>Lewis</surname><given-names>BK</given-names></name><name><surname>Bash</surname><given-names>CN</given-names></name><name><surname>McFarland</surname><given-names>HF</given-names></name><name><surname>Frank</surname><given-names>JA</given-names></name></person-group><article-title>Methylprednisolone effect on brain volume and enhancing lesions in MS before and during IFNbeta-1b</article-title><source>Neurology</source><year>2002</year><volume>59</volume><fpage>688</fpage><lpage>694</lpage><pub-id pub-id-type="pmid">12221158</pub-id></citation></ref><ref id="B31"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kesselring</surname><given-names>J</given-names></name><name><surname>Miller</surname><given-names>DH</given-names></name><name><surname>MacManus</surname><given-names>DG</given-names></name><name><surname>Johnson</surname><given-names>G</given-names></name><name><surname>Milligan</surname><given-names>NM</given-names></name><name><surname>Scolding</surname><given-names>N</given-names></name><name><surname>Compston</surname><given-names>DA</given-names></name><name><surname>McDonald</surname><given-names>WI</given-names></name></person-group><article-title>Quantitative magnetic resonance imaging in multiple sclerosis: the effect of high dose intravenous methylprednisolone</article-title><source>J Neurol Neurosurg Psychiatry</source><year>1989</year><volume>52</volume><fpage>14</fpage><lpage>7</lpage><pub-id pub-id-type="pmid">2709033</pub-id></citation></ref><ref id="B32"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Azar</surname><given-names>ST</given-names></name><name><surname>Yamout</surname><given-names>B</given-names></name></person-group><article-title>Prolactin secretion is increased in patients with multiple sclerosis</article-title><source>Endocr Res</source><year>1999</year><volume>25</volume><fpage>207</fpage><lpage>14</lpage><pub-id pub-id-type="pmid">10382682</pub-id></citation></ref><ref id="B33"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Reder</surname><given-names>AT</given-names></name><name><surname>Lowy</surname><given-names>MT</given-names></name></person-group><article-title>Serum prolactin levels in active multiple sclerosis and during cyclosporin treatment</article-title><source>J Neurol Sci</source><year>1993</year><volume>117</volume><fpage>192</fpage><lpage>6</lpage><pub-id pub-id-type="pmid">8410056</pub-id><pub-id pub-id-type="doi">10.1016/0022-510X(93)90173-V</pub-id></citation></ref><ref id="B34"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Heesen</surname><given-names>C</given-names></name><name><surname>Gold</surname><given-names>SM</given-names></name><name><surname>Bruhn</surname><given-names>M</given-names></name><name><surname>Monch</surname><given-names>A</given-names></name><name><surname>Schulz</surname><given-names>KH</given-names></name></person-group><article-title>Prolactin stimulation in multiple sclerosis – an indicator of disease subtypes and activity?</article-title><source>Endocr Res</source><year>2002</year><volume>28</volume><fpage>9</fpage><lpage>18</lpage><pub-id pub-id-type="pmid">12108793</pub-id><pub-id pub-id-type="doi">10.1081/ERC-120004533</pub-id></citation></ref><ref id="B35"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Vera-Lastra</surname><given-names>O</given-names></name><name><surname>Jara</surname><given-names>LJ</given-names></name><name><surname>Espinoza</surname><given-names>LR</given-names></name></person-group><article-title>Prolactin and autoimmunity</article-title><source>Autoimmun Rev</source><year>2002</year><volume>1</volume><fpage>360</fpage><lpage>364</lpage><pub-id pub-id-type="pmid">12848992</pub-id><pub-id pub-id-type="doi">10.1016/S1568-9972(02)00081-2</pub-id></citation></ref><ref id="B36"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Koller</surname><given-names>M</given-names></name><name><surname>Kotzmann</surname><given-names>H</given-names></name><name><surname>Clodi</surname><given-names>M</given-names></name><name><surname>Riedl</surname><given-names>M</given-names></name><name><surname>Luger</surname><given-names>A</given-names></name></person-group><article-title>Effect of elevated serum prolactin concentrations on the immunophenotype of human lymphocytes, mitogen-induced proliferation and phagocytic activity of polymorphonuclear cells</article-title><source>Eur J Clin Invest</source><year>1997</year><volume>27</volume><fpage>662</fpage><lpage>666</lpage><pub-id pub-id-type="pmid">9279529</pub-id><pub-id pub-id-type="doi">10.1046/j.1365-2362.1997.1670722.x</pub-id></citation></ref><ref id="B37"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Matera</surname><given-names>L</given-names></name><name><surname>Galetto</surname><given-names>A</given-names></name><name><surname>Geuna</surname><given-names>M</given-names></name><name><surname>Vekemans</surname><given-names>K</given-names></name><name><surname>Ricotti</surname><given-names>E</given-names></name><name><surname>Contarini</surname><given-names>M</given-names></name><name><surname>Moro</surname><given-names>F</given-names></name><name><surname>Basso</surname><given-names>G</given-names></name></person-group><article-title>Individual and combined effect of granulocyte-macrophage colony-stimulating factor and prolactin on maturation of dendritic cells from blood monocytes under serum-free conditions</article-title><source>Immunology</source><year>2000</year><volume>100</volume><fpage>29</fpage><lpage>36</lpage><pub-id pub-id-type="pmid">10809956</pub-id><pub-id pub-id-type="doi">10.1046/j.1365-2567.2000.00996.x</pub-id></citation></ref><ref id="B38"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Perez Castro</surname><given-names>C</given-names></name><name><surname>Penalva</surname><given-names>R</given-names></name><name><surname>Paez Pereda</surname><given-names>M</given-names></name><name><surname>Renner</surname><given-names>U</given-names></name><name><surname>Reul</surname><given-names>JM</given-names></name><name><surname>Stalla</surname><given-names>GK</given-names></name><name><surname>Holsboer</surname><given-names>F</given-names></name><name><surname>Arzt</surname><given-names>E</given-names></name></person-group><article-title>Early activation of thyrotropin-releasing-hormone and prolactin plays a critical role during a T cell-dependent immune response</article-title><source>Endocrinology</source><year>1999</year><volume>140</volume><fpage>690</fpage><lpage>697</lpage><pub-id pub-id-type="pmid">9927295</pub-id><pub-id pub-id-type="doi">10.1210/en.140.2.690</pub-id></citation></ref><ref id="B39"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Krishnan</surname><given-names>N</given-names></name><name><surname>Thellin</surname><given-names>O</given-names></name><name><surname>Buckley</surname><given-names>DJ</given-names></name><name><surname>Horseman</surname><given-names>ND</given-names></name><name><surname>Buckley</surname><given-names>AR</given-names></name></person-group><article-title>Prolactin suppresses glucocorticoid-induced thymocyte apoptosis in vivo</article-title><source>Endocrinology</source><year>2003</year><volume>144</volume><fpage>2102</fpage><lpage>2110</lpage><pub-id pub-id-type="pmid">12697719</pub-id><pub-id pub-id-type="doi">10.1210/en.2003-0053</pub-id></citation></ref><ref id="B40"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Sarlis</surname><given-names>NJ</given-names></name><name><surname>Chanock</surname><given-names>SJ</given-names></name><name><surname>Nieman</surname><given-names>LK</given-names></name></person-group><article-title>Cortisolemic indices predict severe infections in Cushing syndrome due to ectopic production of adrenocorticotropin</article-title><source>J Clin Endocrinol Metab</source><year>2000</year><volume>85</volume><fpage>42</fpage><lpage>47</lpage><pub-id pub-id-type="pmid">10634361</pub-id><pub-id pub-id-type="doi">10.1210/jc.85.1.42</pub-id></citation></ref><ref id="B41"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Rupprecht</surname><given-names>M</given-names></name><name><surname>Rupprecht</surname><given-names>R</given-names></name><name><surname>Koch</surname><given-names>HU</given-names></name><name><surname>Haack</surname><given-names>D</given-names></name><name><surname>Muller</surname><given-names>OA</given-names></name><name><surname>Hornstein</surname><given-names>OP</given-names></name></person-group><article-title>Multihormonal response to dexamethasone. A study in atopic dermatitis and normal controls</article-title><source>Acta Derm Venereol</source><year>1991</year><volume>71</volume><fpage>214</fpage><lpage>218</lpage><pub-id pub-id-type="pmid">1678223</pub-id></citation></ref><ref id="B42"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hubina</surname><given-names>E</given-names></name><name><surname>Nagy</surname><given-names>GM</given-names></name><name><surname>Toth</surname><given-names>BE</given-names></name><name><surname>Ivan</surname><given-names>G</given-names></name><name><surname>Gorombey</surname><given-names>Z</given-names></name><name><surname>Szabolcs</surname><given-names>I</given-names></name><name><surname>Kovacs</surname><given-names>L</given-names></name><name><surname>Goth</surname><given-names>MI</given-names></name></person-group><article-title>Dexamethasone and adrenocorticotropin suppress prolactin secretion in humans</article-title><source>Endocrine</source><year>2002</year><volume>18</volume><fpage>215</fpage><lpage>219</lpage><pub-id pub-id-type="pmid">12450312</pub-id><pub-id pub-id-type="doi">10.1385/ENDO:18:3:215</pub-id></citation></ref><ref id="B43"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Zorzon</surname><given-names>M</given-names></name><name><surname>Zivadinov</surname><given-names>R</given-names></name><name><surname>Locatelli</surname><given-names>L</given-names></name><name><surname>Giuntini</surname><given-names>D</given-names></name><name><surname>Toncic</surname><given-names>M</given-names></name><name><surname>Bosco</surname><given-names>A</given-names></name><name><surname>Nasuelli</surname><given-names>D</given-names></name><name><surname>Bratina</surname><given-names>A</given-names></name><name><surname>Tommasi</surname><given-names>MA</given-names></name><name><surname>Rudick</surname><given-names>RA</given-names></name><name><surname>Cazzato</surname><given-names>G</given-names></name></person-group><article-title>Long-term effects of intravenous high dose methylprednisolone pulses on bone mineral density in patients with multiple sclerosis</article-title><source>Eur J Neurol</source><year>2005</year><volume>12</volume><fpage>550</fpage><lpage>556</lpage><pub-id pub-id-type="pmid">15958096</pub-id><pub-id pub-id-type="doi">10.1111/j.1468-1331.2005.00988.x</pub-id></citation></ref><ref id="B44"><citation citation-type="other"><article-title>Sylvia Lawry Center for Multiple Sclerosis Research</article-title><ext-link ext-link-type="uri" xlink:href="http://www.slcmsr.net/en/partner/cooperations.html"></ext-link></citation></ref></ref-list><sec sec-type="display-objects"><title>Figures and Tables</title><fig position="float" id="F1"><label>Figure 1</label><caption><p>Study flow chart</p></caption><graphic xlink:href="1471-2377-6-19-1"></graphic></fig><fig position="float" id="F2"><label>Figure 2</label><caption><p>Time course of the mean number of active lesions on monthly Gd-enhanced brain MRI.</p></caption><graphic xlink:href="1471-2377-6-19-2"></graphic></fig><table-wrap position="float" id="T1"><label>Table 1</label><caption><p>Demographic characteristics and primary outcome measure, the number of active lesions/scan (Mean [SEM])</p></caption><table frame="hsides" rules="groups"><thead><tr><td align="center"><bold>Patient</bold></td><td align="center"><bold>Age</bold></td><td align="center"><bold>Sex</bold></td><td align="center"><bold>EDSS</bold></td><td align="center"><bold>Duration of disease</bold></td><td align="center" colspan="2"><bold>Mean number of active lesions per monthly scan</bold></td><td align="center"><bold>Change, mean lesion number</bold></td></tr></thead><tbody><tr><td></td><td></td><td align="center">F/M</td><td></td><td align="center">years</td><td align="center">baseline period</td><td align="center">treatment period</td><td align="center">%</td></tr><tr><td colspan="8"><hr></hr></td></tr><tr><td align="center">All patients</td><td align="center">32.7 [1.4]</td><td align="center">8/1</td><td align="center">1.5 [0.33]</td><td align="center">6.3 [2.0]</td><td align="center"><bold>3.55 [0.78]</bold></td><td align="center"><bold>2.15 [0.69]</bold></td><td align="center">- 39.4 <break></break>p = 0.013*</td></tr><tr><td colspan="8"><hr></hr></td></tr><tr><td align="center">01</td><td align="center">25</td><td align="center">F</td><td align="center">0</td><td align="center">1</td><td align="center">1</td><td align="center">0,5</td><td align="center">- 50</td></tr><tr><td align="center">02</td><td align="center">32</td><td align="center">F</td><td align="center">0</td><td align="center">2.5</td><td align="center">1.83</td><td align="center">0</td><td align="center">- 100</td></tr><tr><td align="center">03</td><td align="center">31</td><td align="center">F</td><td align="center">2.0</td><td align="center">5</td><td align="center">7.67</td><td align="center">5.83</td><td align="center">- 34</td></tr><tr><td align="center">04</td><td align="center">34</td><td align="center">F</td><td align="center">1.5</td><td align="center">4</td><td align="center">2.33</td><td align="center">2.83</td><td align="center">+ 21</td></tr><tr><td align="center">05</td><td align="center">34</td><td align="center">F</td><td align="center">1.0</td><td align="center">0.3</td><td align="center">6</td><td align="center">3.67</td><td align="center">- 38</td></tr><tr><td align="center">06</td><td align="center">36</td><td align="center">M</td><td align="center">2.5</td><td align="center">11.3</td><td align="center">4.5</td><td align="center">0.67</td><td align="center">- 85</td></tr><tr><td align="center">07</td><td align="center">40</td><td align="center">F</td><td align="center">2.5</td><td align="center">15</td><td align="center">1</td><td align="center">0.17</td><td align="center">- 83</td></tr><tr><td align="center">08</td><td align="center">33</td><td align="center">F</td><td align="center">2.5</td><td align="center">15</td><td align="center">4.83</td><td align="center">4.17</td><td align="center">- 14</td></tr><tr><td align="center">09</td><td align="center">30</td><td align="center">F</td><td align="center">1.5</td><td align="center">3</td><td align="center">2.67</td><td align="center">1.5</td><td align="center">- 38</td></tr><tr><td></td><td></td><td></td><td></td><td></td><td align="center" colspan="2"><bold>Median change</bold></td><td align="center"><bold>- 43.8 %</bold></td></tr><tr><td></td><td></td><td></td><td></td><td></td><td align="center" colspan="2"><bold>Mean change</bold></td><td align="center"><bold>- 46.4 %</bold></td></tr></tbody></table><table-wrap-foot><p>* p for testing baseline vs. treatment period (Wilcoxon Matched-Pairs Signed-Ranks test for related samples).</p></table-wrap-foot></table-wrap><table-wrap position="float" id="T2"><label>Table 2</label><caption><p>T2 lesion load and brain fractional volume (Mean [SEM]).</p></caption><table frame="hsides" rules="groups"><thead><tr><td></td><td align="center" colspan="3"><bold>Baseline period</bold></td><td align="center" colspan="4"><bold>Treatment period</bold></td></tr></thead><tbody><tr><td></td><td align="center">Month 1</td><td align="center">Month 6</td><td align="center">Change (mth 6 vs. mth 1)</td><td align="center">Month 7</td><td align="center">Month 12</td><td align="center">Change (mth 12 vs. mth 7)</td><td align="center">Change (mth 12 vs. mth 6)</td></tr><tr><td colspan="8"><hr></hr></td></tr><tr><td align="left">T2 lesion load (ml)</td><td align="center">19.93 [4.8]</td><td align="center">22.49 [4.64]</td><td align="center">+ 13 %<break></break>p &lt; 0.001</td><td align="center">20.68 [4.23]</td><td align="center">17.70 [4.17]</td><td align="center">- 14 %<break></break>p = 0.001</td><td align="center">- 21%<break></break>p = 0.001</td></tr><tr><td align="left">BFV (%)</td><td align="center">86.4 [1.4]</td><td align="center">86.1 [1.8]</td><td align="center">- 0.35 %<break></break>n.s.</td><td align="center">85.9 [1.9]</td><td align="center">83.9 [1.8]</td><td align="center">-2.33 %<break></break>n.s.</td><td align="center">-2.56%<break></break>n.s.</td></tr></tbody></table><table-wrap-foot><p>Multivariate Wilk's test for T2 lesion load, p = 0.002, and for BFV, p = 0.086; p values given in the table are for univariate F tests.</p></table-wrap-foot></table-wrap><table-wrap position="float" id="T3"><label>Table 3</label><caption><p>Mean [SEM] of plasma hormone concentrations during the baseline and treatment period, and results of neuroendocrinological tests</p></caption><table frame="hsides" rules="groups"><thead><tr><td></td><td align="center"><bold>Baseline period</bold></td><td align="center"><bold>Treatment period</bold></td><td align="center">p*</td></tr></thead><tbody><tr><td align="left"><bold>Plasma hormone concentrations (means of monthly tests)</bold></td><td></td><td></td><td></td></tr><tr><td align="left">Prolactin (ng/ml)</td><td align="center">10.2 [0.8]*</td><td align="center">8.7 [0.7]*</td><td align="center">0.027</td></tr><tr><td align="left">Cortisol (ng/ml)</td><td align="center">114.4 [23.2]</td><td align="center">122.4 [22.8]</td><td align="center">n.s.</td></tr><tr><td align="left">ACTH (pg/ml)</td><td align="center">17.4 [2.3]</td><td align="center">19.9 [4.3]</td><td align="center">n.s.</td></tr><tr><td align="left"><bold>DEX-CRH test</bold></td><td></td><td></td><td></td></tr><tr><td align="left">CORT max (ng/ml)</td><td align="center">39.7 [8]</td><td align="center">41.1 [14]</td><td align="center">n.s.</td></tr><tr><td align="left">CORT AUC</td><td align="center">147.5 [30]</td><td align="center">152.8 [55]</td><td align="center">n.s.</td></tr><tr><td align="left">ACTH max (pg/ml)</td><td align="center">20.4 [5]</td><td align="center">22.5 [11]</td><td align="center">n.s.</td></tr><tr><td align="left">ACTH AUC</td><td align="center">49.4 [7]</td><td align="center">46.6 [11]</td><td align="center">n.s.</td></tr><tr><td align="left"><bold>ACTH test</bold></td><td></td><td></td><td></td></tr><tr><td align="left">ACTH base (pg/ml)</td><td align="center">24.40 [12.21]</td><td align="center">28.69 [7.23]</td><td align="center">n.s.</td></tr><tr><td align="left">CORT base (ng/ml)</td><td align="center">175.1 [22.6]</td><td align="center">169.9 [22.4]</td><td align="center">n.s.</td></tr><tr><td align="left">CORT 60 min (ng/ml)</td><td align="center">330.7 [59]</td><td align="center">275.8 [26.5]</td><td align="center">n.s.</td></tr><tr><td align="left">Delta Cort (ng/ml)</td><td align="center">149.70 [35.67]</td><td align="center">163.00 [32.40]</td><td align="center">n.s.</td></tr></tbody></table><table-wrap-foot><p>* p for comparisons of baseline vs. treatment periods, MANOVA</p></table-wrap-foot></table-wrap><table-wrap position="float" id="T4"><label>Table 4</label><caption><p>Plasma cytokine receptor and VCAM-1 concentrations (Mean [SEM])</p></caption><table frame="hsides" rules="groups"><thead><tr><td></td><td align="center"><bold>Baseline period</bold></td><td align="center"><bold>Treatment period</bold></td><td align="center">p*</td></tr></thead><tbody><tr><td align="left">sTNF-R I (ng/ml)</td><td align="center">1.4 [0.05]</td><td align="center">1.4 [0.09]</td><td align="center">n.s.</td></tr><tr><td align="left">sTNF-R II (ng/ml)</td><td align="center">3.3 [0.3]</td><td align="center">3.4 [0.2]</td><td align="center">n.s.</td></tr><tr><td align="left">IL-1 ra (pg/ml)</td><td align="center">262.9 [43.2]</td><td align="center">246.4 [37.8]</td><td align="center">n.s.</td></tr><tr><td align="left">sVCAM-1 (ng/ml)</td><td align="center">430.7 [28.9]</td><td align="center">484.6 [52.6]</td><td align="center">n.s.</td></tr></tbody></table><table-wrap-foot><p>* p for comparisons of baseline vs. treatment periods, MANOVA</p></table-wrap-foot></table-wrap></sec></back></article>